Mark Rubinstein to Immunotherapy, Adoptive
This is a "connection" page, showing publications Mark Rubinstein has written about Immunotherapy, Adoptive.
Connection Strength
1.451
-
Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host. J Am Coll Surg. 2012 Apr; 214(4):700-7; discussion 707-8.
Score: 0.370
-
B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity. J Immunother Cancer. 2022 01; 10(1).
Score: 0.183
-
Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8+ T cells. Eur J Immunol. 2020 09; 50(9):1386-1399.
Score: 0.164
-
Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. Cancer Res. 2018 06 01; 78(11):3067-3074.
Score: 0.141
-
Inducible Enhancement of T Cell Function and Anti-tumor Activity after Adoptive Transfer. Mol Ther. 2017 09 06; 25(9):1995-1996.
Score: 0.135
-
Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis. Cancer Immunol Immunother. 2017 Jun; 66(6):737-751.
Score: 0.131
-
Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling. Clin Cancer Res. 2015 Jun 01; 21(11):2546-57.
Score: 0.115
-
The inducible costimulator augments Tc17 cell responses to self and tumor tissue. J Immunol. 2015 Feb 15; 194(4):1737-47.
Score: 0.113
-
Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignancies. Oncoimmunology. 2021; 10(1):1959101.
Score: 0.045
-
Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines. Front Immunol. 2019; 10:263.
Score: 0.038
-
Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother. 2007 Jan; 30(1):40-53.
Score: 0.016